Mefenamic Acid: Pharmacological Profile, Clinical Applications, and Emerging Therapeutic Perspectives with Special Reference to Dysmenorrhoea
Scholastic Medical Sciences · 27.02.2026 · 01
DOI: 10.67735/scms.2026.03.0160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scholastic Medical Sciences, online erschienen am 27.02.2026. Verfasst von Gulafshan Fatima.
Abstract (Originalsprache)
Mefenamic acid (MFA) is an anthranilic acid derivative belonging to the fenamate class of non-steroidal anti-inflammatory drugs (NSAIDs). It is widely used for the management of mild to moderate pain, particularly in dysmenorrhoea. Despite its long-standing clinical use, its physicochemical limitations, short half-life, and emerging therapeutic applications warrant renewed attention. This review summarizes the pharmacological characteristics, mechanism of action, pharmacokinetics, clinical indications, contraindications, and recent randomized controlled trials (RCTs) evaluating its role in dysmenorrhoea. Additionally, emerging evidence regarding its neurological and adjunctive oncological applications is discussed. While mefenamic acid remains an effective therapeutic agent, its adverse effect profile and formulation challenges must be carefully considered.
Zitieren
APA
Fatima, G. (2026). Mefenamic Acid: Pharmacological Profile, Clinical Applications, and Emerging Therapeutic Perspectives with Special Reference to Dysmenorrhoea. Scholastic Medical Sciences, 01. https://doi.org/10.67735/scms.2026.03.0160
Vancouver
Fatima G. Mefenamic Acid: Pharmacological Profile, Clinical Applications, and Emerging Therapeutic Perspectives with Special Reference to Dysmenorrhoea. Scholastic Medical Sciences. 2026:01. doi:10.67735/scms.2026.03.0160
BibTeX
@article{Fatima2026,
author = {Fatima, Gulafshan},
title = {Mefenamic Acid: Pharmacological Profile, Clinical Applications, and Emerging Therapeutic Perspectives with Special Reference to Dysmenorrhoea},
journal = {Scholastic Medical Sciences},
year = {2026},
pages = {01},
doi = {10.67735/scms.2026.03.0160}
}
EUVIMED